Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.5% - Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price rose 5.5% during trading on Monday . The company traded as high as $6.50 and last traded at $6.36. Approximately 5,209,043 shares traded hands during trading, a decline of 23% from the average daily volume of 6,721,588 shares. The stock had previously closed at $6.03.

Analyst Upgrades and Downgrades

Several research firms recently commented on RXRX. Jefferies Financial Group cut their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $9.25.

Recursion Pharmaceuticals Stock Up 15.9 %

The firm's 50 day simple moving average is $6.76 and its 200-day simple moving average is $7.18. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -4.57 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the business earned ($0.43) EPS. Recursion Pharmaceuticals's revenue was up 147.6% on a year-over-year basis. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,647,966. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total transaction of $94,800.00. Following the completion of the sale, the chief financial officer now owns 1,426,506 shares of the company's stock, valued at $9,015,517.92. This trade represents a 1.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,788 shares of company stock worth $724,691 in the last 90 days. Corporate insiders own 15.75% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $25,000. Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after purchasing an additional 4,091 shares during the period. Amalgamated Bank lifted its stake in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after buying an additional 2,459 shares during the last quarter. KBC Group NV boosted its holdings in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after buying an additional 3,377 shares during the period. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals in the 3rd quarter valued at about $69,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.